Scientist robot gets venture funding from Omega

Andrew Alliance closed a Series B financing of an undisclosed amount to further develop and market its scientific robots. One of its most successful products is the co-worker Andrew robot, which was awarded "Product of the Year" by the Society of Laboratory Automation and Screening in 2013. The Andrew robot is designed to perform a routine task called "liquid handling", a task that can be stressful and repetitive and cause health risks if not done properly. The robot frees scientists from a mundane task that is "wasting intellectual talents," and can make up for its cost in under a year, said Andrew Alliance CEO Piero Zucchelli. The financing, which came from healthcare fund Omega Funds, will help Andrew Alliance establish a U.S. market as it also prepares to open a new office in Boston. Story

Suggested Articles

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.

Akoya Biosciences raised $50 million to help boost its commercialization in research, drug development and clinical testing markets.